Table 2 Characteristics of study population
Characteristics | Women infected at ANC-1 (enrolment) (N = 120) | Women infected at Delivery (N = 120) | Women infected at ANC-1 and at delivery (N = 42) | P |
|---|---|---|---|---|
Age at enrolment (years, mean ± SD) | 23.9 (±5.7) | 26.5 (± 6.1) | 21.5 (5.6) |  < 0.001 |
Parasite density by LM (parasites/μl, Median (IQR)) | ||||
 ANC-1 | 903 (324.5–2308.5) | – | 1752.5 (558.5–5373.5) | 0.01 |
 Delivery | – | 1955.7 (565.2–9733) | 2268 (835–15,485) | 0.84 |
MiP preventive strategy | ||||
 IPTp-SP | 67 (55.8) | 58 (48.3) | 20 (47.6) | 0.40 |
 CSST/IPTp-SP | 53 (44.2) | 62 (51.7) | 22 (52.4) |  |
Gravidity | ||||
  ≤ 2 | 63 (52.5) | 35 (29.2) | 32 (76.2) |  < 0.001 |
  > 2 | 57 (47.5) | 85 (70.8) | 10 (23.8) |  |
ITN usagea | ||||
 Night before ANC-1 | 103 (92.8) | – | 24 (72.7) | 0.004 |
 Night before delivery | – | 69 (62.2) | 24 (72.7) | 0.30 |
IPTp-SP doses during pregnancy | ||||
 < 3 | – | 82 (68.3) | 33 (78.6) | 0.21 |
  ≥ 3 | – | 38 (31.7) | 9 (21.4) |  |
AL treatment during pregnancy | ||||
 0 | – | 67 (55.8) | 13 (31.0) | 0.02 |
 1 | – | 33 (27.5) | 19 (45.2) |  |
 ≥ 2 |  | 20 (16.7) | 10 (23.8) |  |
Timing AL treatment to delivery | ||||
 No treatment |  | 67 (55.8) | 13 (31.0) | 0.05 |
 4 to 28 days | – | 18 (15.0) | 8 (19.0) |  |
 29 to 42 days | – | 13 (10.8) | 10 (23.8) |  |
 43 to 63 days |  | 13 (10.8) | 5 (11.9) |  |
  ≥ 64 days |  | 9 (7.5) | 4 (14.3) |  |
Haemoglobin level at deliverya | ||||
 < 11 g/dl | – | 63 (53.4) | 20 (50.0) | 0.72 |
 ≥ 11 g/dl | – | 55 (46.6) | 20 (50.0) |  |
Malaria episode during pregnancy | ||||
 ≤ 2 | – | 58 (48.3) | 0 (0.0) |  < 0.001 |
 > 2 | – | 62 (51.7) | 42 (100) |  |
Triple dhfr 51/59/108 mutation at deliverya | ||||
 No |  | 19 (28.8) | 6 (35.3) | 0.60 |
 Yes |  | 46 (71.2) | 11 (64.7) |  |